RxDoctor Payments Data

Joe Whitaker, MD

Internal Medicine · Tampa, FLNPI 1881613859

Payments from drug & device makers

$14,039in general payments, 2019–2025

Across 760 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$2K
  • AbbVie$2K
  • GSK$1K
  • Pfizer$903
  • Amgen$723
  • plus $5K from 50 others

What the payments were for

  • Consulting fees$130%
  • Food & beverage$13,92699%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,039 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$208,350
Medicare patients
518
Services billed
3,315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban169$192,639
OzempicSemaglutide123$157,825
FarxigaDapagliflozin Propanediol90$83,090
RybelsusSemaglutide50$69,404
XareltoRivaroxaban54$66,928
TrulicityDulaglutide49$65,510
Tresiba Flextouch U-100Insulin Degludec34$32,786
JanuviaSitagliptin Phosphate30$29,491
JardianceEmpagliflozin27$28,792
EntrestoSacubitril/Valsartan20$24,354
JanumetSitagliptin Phos/Metformin Hcl25$19,163
MounjaroTirzepatide12$12,094
Lagevrio (Eua)Molnupiravir19$9,656
Breo ElliptaFluticasone/Vilanterol13$7,847
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,808$227,229173 claims
PfizerEliquis$903$192,639169 claims
AstraZenecaFarxiga, Symbicort$2,091$86,041101 claims
Lilly USA, LLCTrulicity, Mounjaro$603$77,60461 claims
Johnson & JohnsonXarelto$341$66,92854 claims
MerckJanuvia, Janumet, Lagevrio (Eua)$77$58,30974 claims
Boehringer IngelheimJardiance$160$28,79227 claims
NovartisEntresto$321$24,35420 claims
GSKBreo Ellipta$1,351$7,84713 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$3,834497 claims
AbbVieSynthroid$1,718$3,03046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →